iBio Inc. (IBIO)
NASDAQ: IBIO
· Real-Time Price · USD
0.77
-0.01 (-0.81%)
At close: Aug 22, 2025, 1:45 PM
-0.81% (1D)
| Bid | 0.76 |
| Market Cap | 12.55M |
| Revenue (ttm) | 375K |
| Net Income (ttm) | -20.99M |
| EPS (ttm) | -0.04 |
| PE Ratio (ttm) | -19.34 |
| Forward PE | -0.93 |
| Analyst | Buy |
| Ask | 0.78 |
| Volume | 366,610 |
| Avg. Volume (20D) | 2,162,829 |
| Open | 0.74 |
| Previous Close | 0.78 |
| Day's Range | 0.74 - 0.82 |
| 52-Week Range | 0.56 - 6.89 |
| Beta | 0.60 |
About IBIO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IBIO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IBIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
iBio Inc. is scheduled to release its earnings on
Sep 19, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 days ago
+0.22%
IBio shares are trading lower after the company an...
Unlock content with
Pro Subscription
1 month ago
+5.63%
iBio shares are trading higher after the company announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake in a mouse model of obesity by 60%.
1 year ago · proactiveinvestors.com
iBio partners with AstralBio to develop obesity treatments using AI-driven platformiBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop n...
